Hand

Spryker Expands App Composition Platform with Stripe as its Global Payment Services Provider

Retrieved on: 
Wednesday, April 3, 2024
Cloud, Payment, Data integration, PSP, Merchant, SLA, Business intelligence, Marketing, Commerce, Hand, Online shopping

BERLIN and NEW YORK, April 03, 2024 (GLOBE NEWSWIRE) -- Spryker , the leading composable commerce platform for sophisticated use cases in B2B, Enterprise Marketplaces, and IoT Commerce, and Stripe, a financial infrastructure platform for businesses, today announced the availability of Stripe on the Spryker App Composition Platform .

Key Points: 
  • BERLIN and NEW YORK, April 03, 2024 (GLOBE NEWSWIRE) -- Spryker , the leading composable commerce platform for sophisticated use cases in B2B, Enterprise Marketplaces, and IoT Commerce, and Stripe, a financial infrastructure platform for businesses, today announced the availability of Stripe on the Spryker App Composition Platform .
  • With the Spryker App Composition Platform, enterprises can facilitate initial integrations in one-click, allowing them to test the value of apps and services on their business quickly without wasting developer days.
  • The Spryker App Composition Platform is growing its third-party services offered across categories including Payment, Business Intelligence, Analytics, Commerce, Customer, Data Integration, Marketing, Operational Cloud, etc.
  • The Spryker App Composition Platform is available for all Spryker Cloud Commerce OS Customers.

ContextLogic Announces Post-Closing Board of Directors and Management Team

Retrieved on: 
Tuesday, April 2, 2024
General counsel, UBS, SAN, Knowledge, Acquisition, Software, Wish (company), Bajaj, Special, Hand, Management

SAN FRANCISCO, April 02, 2024 (GLOBE NEWSWIRE) --  ContextLogic Inc. (d/b/a Wish) (NASDAQ: WISH) (“ContextLogic” or the “Company”) today announced that it will reconstitute its Board of Directors and management team upon completion of its pending transaction under which it will sell substantially all of its operating assets and liabilities, principally comprising its Wish ecommerce platform (the “Asset Sale”), to Qoo10 Pte. Ltd. (“Qoo10”). The transaction is expected to be completed in the second quarter of 2024.

Key Points: 
  • Upon closing, the reconstituted Board will comprise five directors, four of whom will be independent and newly appointed.
  • Rishi Bajaj, Founder, President and Chief Investment Officer at Altai Capital Management and current director at ContextLogic.
  • Bajaj joined the ContextLogic Board in November 2023 and played an active strategic role in structuring the Asset Sale.
  • At the same time, ContextLogic directors Tanzeen Syed, Julie Bradley, Larry Kutscher, Stephanie Tilenius, Hans Tung and Joe Yan will step down from the Board.

Roivant Announces Positive NEPTUNE Study Results for Brepocitinib in NIU, as well as Board Authorization for up to $1.5 Billion Share Repurchase Program, Including Repurchase of Entire Sumitomo Pharma Stake for $648 Million

Retrieved on: 
Tuesday, April 2, 2024
Disease, Macular edema, NIU, Paratriathlon, Arm, Rule, Safety, Risk, Webcast, Inflammation, Patient, NEPTUNE, EDT, Master of Science, Haze, Prednisone, Visual acuity, Therapy, Sumitomo Pharma, Calendar, Share repurchase, JAK, Visual impairment, Physician, Hand, Pediatrics, Pharmaceutical industry

We are also pleased to announce our authorized share repurchase program, and our agreed repurchase of all shares owned by Sumitomo Pharma.

Key Points: 
  • We are also pleased to announce our authorized share repurchase program, and our agreed repurchase of all shares owned by Sumitomo Pharma.
  • The NEPTUNE study enrolled 26 subjects with active NIU who were randomized 2:1 to brepocitinib 45 mg once daily or brepocitinib 15 mg once daily.
  • All week 24 secondary efficacy endpoints, including haze grades, visual acuity, and macular thickness, were also positive and dose responsive.
  • The presentation and webcast details are also available under “Events & Presentations” in the Investors section of the Roivant website at https://investor.roivant.com/news-events/events.

ONWARD® Medical Submits De Novo Application to FDA for its ARC-EX® System

Retrieved on: 
Tuesday, April 2, 2024
De novo, DPT, BCI, Arm, Paralysis, Evaluation, Doctor of Philosophy, Quality of life, Euronext, BDD, Annual report, Craig Hospital, Spinal cord, Safety, ARC, Food, Marketing, FDA, SCI, NCS, Movement, Hand, Medical device

EINDHOVEN, the Netherlands, April 02, 2024 (GLOBE NEWSWIRE) -- ONWARD Medical N.V. (Euronext: ONWD), the medical technology company creating innovative spinal cord stimulation therapies to improve or restore movement, function, and independence in people with spinal cord injury (SCI), today announces it has submitted its De Novo application to the US Food and Drug Administration (FDA) to allow marketing of its breakthrough ARC-EX System to restore function of the upper extremities after SCI.

Key Points: 
  • The submission marks an historic milestone for the Company in its mission to restore mobility and function for people with SCI.
  • Once cleared by the FDA, ARC-EX will be the first-ever spinal cord stimulation therapy to restore hand and arm function after SCI and the first commercial product for ONWARD Medical.
  • “We are delighted to be one step closer to bringing our breakthrough ARC-EX System to people living with SCI after submitting this De Novo application for regulatory clearance in the United States,” said ONWARD Medical CEO Dave Marver.
  • The ARC-EX System was previously awarded FDA Breakthrough Device Designation (BDD) for upper limb function, which provided prioritized FDA review, the opportunity to interact with FDA experts, and the potential for additional reimbursement.

Nanox Announces Fourth Quarter of 2023 Financial Results and Provides Business Update

Retrieved on: 
Monday, April 1, 2024
Research, PIN, LTD, Intermountain Health, Radiology, Exercise, Medical imaging, Patient, Health, Fatty liver disease, Action Replay, Policy, Sale, AI, D&O, Google Images, Teleradiology, NANO, GAAP, ARC, Depreciation, Marketing, FDA, Vertebral compression fracture, Hand, Cryptocurrency

PETAH TIKVA, Israel, April 01, 2024 (GLOBE NEWSWIRE) -- NANO-X IMAGING LTD (NASDAQ: NNOX) (“Nanox” or the “Company”), an innovative medical imaging technology company, today announced results for the fourth quarter ended December 31, 2023 and provided a business update.

Key Points: 
  • Fourth Quarter 2023 Highlights and Recent Developments:
    Generated $2.4 million in revenue in the fourth quarter of 2023, compared to $2.1 million in the fourth quarter of 2022.
  • “I am incredibly proud to announce another strong quarter and year for Nanox,” said Erez Meltzer, Nanox Chief Executive Officer.
  • “First and foremost, we achieved a pivotal milestone in fiscal year 2023, getting FDA clearance for the Nanox ARC systems and deploying them in the key US market.
  • During the fourth quarter of 2023, Nanox AI continued to complete pilot programs with marketplaces, marketplace costumers and health organizations in anticipation of full deployment of its products.

Townsquare Announces Repurchase of Just Under 10% of Outstanding Shares Reaffirms Q1’24 and FY’24 Guidance

Retrieved on: 
Monday, April 1, 2024
MSG, Adjustment, Oaktree Capital Management, Hand, Pharmaceutical industry

The purchase price reflects an 11% discount from the closing price of the Class A common stock on March 28, 2024.

Key Points: 
  • The purchase price reflects an 11% discount from the closing price of the Class A common stock on March 28, 2024.
  • This transaction follows Townsquare’s June 2023 repurchase of 1.5 million shares from MSG at $9.70 per share, and March 2021 repurchase of 12.6 million shares and warrants from Oaktree Capital Management, L.P. at $6.40 per share.
  • In 2023, Townsquare’s Cash Flow from Operations increased 35% year-over-year to $68 million, or approximately $4.07 per basic share based on shares outstanding as of March 28, 2024.
  • Since 2021, we have repurchased 16.2 million shares at an average price of $7.19, while simultaneously reducing leverage.

Descartes Acquires OCR

Retrieved on: 
Thursday, March 28, 2024
DSG, Descartes Systems Group, Classification, Artificial intelligence, SAP, OCR, TSX, Commerce, Visual Compliance, Hand

WATERLOO, Ontario and ATLANTA, March 28, 2024 (GLOBE NEWSWIRE) -- Descartes Systems Group (TSX:DSG) (Nasdaq:DSGX), the global leader in uniting logistics-intensive businesses in commerce, announced that it has acquired OCR Services, Inc. (“OCR”), a leading provider of global trade compliance solutions and content.

Key Points: 
  • WATERLOO, Ontario and ATLANTA, March 28, 2024 (GLOBE NEWSWIRE) -- Descartes Systems Group (TSX:DSG) (Nasdaq:DSGX), the global leader in uniting logistics-intensive businesses in commerce, announced that it has acquired OCR Services, Inc. (“OCR”), a leading provider of global trade compliance solutions and content.
  • Similar to Descartes, OCR monitors regulatory sources and updates their trade data content libraries daily.
  • “The OCR team brings a wealth of domain expertise in global trade compliance to Descartes, including experience leveraging artificial intelligence (AI) in the content management process,” said Andrew Roszko, Chief Commercial Officer at Descartes.
  • We’re thrilled to welcome the OCR employees, customers and partners into the Descartes family.”
    OCR is headquartered in Rockville, Maryland.

Veritex Holdings, Inc. Announces Stock Buyback Program and Investment Portfolio Restructuring

Retrieved on: 
Thursday, March 28, 2024
AFS, Sale, Hand, Share repurchase, Security (finance)

DALLAS, March 28, 2024 (GLOBE NEWSWIRE) -- Veritex Holdings, Inc. (Nasdaq: VBTX) (“Veritex” or "the Company”), the parent holding company for Veritex Community Bank, today announced that its Board of Directors (the "Board") authorized a stock buyback program (the "Stock Buyback Program") pursuant to which the Company is authorized to purchase up to $50.0 million shares of the Company’s outstanding common stock.

Key Points: 
  • DALLAS, March 28, 2024 (GLOBE NEWSWIRE) -- Veritex Holdings, Inc. (Nasdaq: VBTX) (“Veritex” or "the Company”), the parent holding company for Veritex Community Bank, today announced that its Board of Directors (the "Board") authorized a stock buyback program (the "Stock Buyback Program") pursuant to which the Company is authorized to purchase up to $50.0 million shares of the Company’s outstanding common stock.
  • The Stock Buyback Program is expected to be funded using the Company’s cash on hand and cash from operations of Veritex Community Bank.
  • Repurchases under the Stock Buyback Program may be made, from time to time, in amounts and at prices the Company deems appropriate.
  • The Stock Buyback Program does not obligate the Company to purchase any shares of its common stock.

AM Resources Identifies 49 New Pegmatites on its Significant Land Package in the Austrian Pegmatite Belt

Retrieved on: 
Thursday, March 28, 2024
Pressure, Geology, News, Acquisition, Disclosure, QP, AMR, Mineral, Plant, Lithium, Hand, Suite (music)

Recently announced 1,500 km2 land package gives AM Resources control over a large area of the Austrian Pegmatite Belt (see press release dated March 21, 2024).

Key Points: 
  • Recently announced 1,500 km2 land package gives AM Resources control over a large area of the Austrian Pegmatite Belt (see press release dated March 21, 2024).
  • These pegmatites consolidate the Company’s strategic position in one of Austria’s most prospective lithium areas.
  • Located just 1 km southwest of the Frederick property, the Valerie property hosts 27 pegmatites over an area of 7.2 km2.
  • Mr. Lafleur is independent from the Company and has reviewed and approved the disclosure of the AM Resources geological information.

Hamilton Thorne Reports Record Revenue and EBITDA for the Quarter and Year Ended December 31, 2023

Retrieved on: 
Wednesday, March 27, 2024
Financial statement, Growth, Infertility, International, IVF, Travel, EDT, Acquisition, Laboratory, Consumables, Adjustment, Investment, Depreciation, Analysis, Marketing, Hand, Bookkeeping

Results of Operations for the Year ended December 31, 2023

Key Points: 
  • Results of Operations for the Year ended December 31, 2023
    Hamilton Thorne sales increased 16% to $67,225,476 for the year-ended December 31, 2023, an increase of $9,047,409 from $58,178,067 during the previous year.
  • Consumable sales in 2023 outpaced the Company’s overall growth despite being affected by the recall of certain products by one of the Company’s contract manufacturers.
  • We are expecting first quarter 2024 reported revenues of between $19.0 to 19.4M, with organic growth for the quarter of approximately 8%.
  • Financial Statements and accompanying Management Discussion and Analysis for the periods are available on www.sedar.com and the Hamilton Thorne website.